



Attorney Docket No.: 4401.214-US

RECEIVED  
JUL 07 2003  
PATENT  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Dyrberg et al.

Application No.: 09/847,623

Group Art Unit: 1639

Filed: May 2, 2001

Examiner: B. Celsa

Confirmation No: 6709

For: Treatment of Type I Diabetes

**RESPONSE TO ELECTION REQUIREMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:


In response to election of species requirement stated in the Office Action mailed June 6, 2002, Applicant hereby elects with traverse Asp-B25 human insulin as the species for initial examination on the merits only. Claims 6, 8, 9, and 10 read thereon. Applicant respectfully requests that if the species elected is found allowable, the Examiner enlarge the search to encompass non-elected subject matter.

The basis for traverse of the restriction/election requirement is that there would not be a serious burden on the Examiner to examine the entire application on the merits.

Applicant hereby reserves the right to file continuing applications directed to the non-elected subject matter.

Respectfully submitted,

Date: June 30, 2003

  
\_\_\_\_\_  
Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE